General Actions (Not specific medical benefits for the user)
| Core Action | Mechanism |
| Increases Insulin Action (Linagliptin) | Linagliptin blocks the enzyme DPP-4, which breaks down incretin hormones (GLP-1). This action increases insulin release and decreases glucose production after meals. |
| Increases Glucose Excretion (Empagliflozin) | Empagliflozin blocks the SGLT2 protein in the kidneys, causing the body to excrete excess glucose through the urine, reducing blood sugar levels independent of insulin. |
| Cardiovascular & Renal Protection | The Empagliflozin component is proven to reduce the risk of cardiovascular death and hospitalization for heart failure, and to slow the progression of chronic kidney disease. |
| Comprehensive Glycemic Control | The complementary actions provide effective $24\text{ hour}$ glucose control, targeting both insulin signaling and glucose filtration to achieve robust $HbA_{1c}$ goals. |
⚠️ Important Safety Note:
Limpa 5/25mg Tablet is a prescription anti-diabetic medication.
Warning! You must be logged in to submit a review.
Login
Customer questions & answers
Customer reviews
0 out of 5